Cargando…
Information and vaccine hesitancy: Evidence from the early stage of the vaccine roll-out in 28 European countries
The success of mass vaccination programs against SARS-CoV-2 hinges on the public’s acceptance of the vaccines. During a vaccine roll-out, individuals have limited information about the potential side-effects and benefits. Given the public health concern of the COVID pandemic, providing appropriate i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491558/ https://www.ncbi.nlm.nih.gov/pubmed/36129897 http://dx.doi.org/10.1371/journal.pone.0273555 |
_version_ | 1784793300278968320 |
---|---|
author | Agosti, Francesca Toffolutti, Veronica Cavalli, Nicolò Nivakoski, Sanna Mascherini, Massimiliano Aassve, Arnstein |
author_facet | Agosti, Francesca Toffolutti, Veronica Cavalli, Nicolò Nivakoski, Sanna Mascherini, Massimiliano Aassve, Arnstein |
author_sort | Agosti, Francesca |
collection | PubMed |
description | The success of mass vaccination programs against SARS-CoV-2 hinges on the public’s acceptance of the vaccines. During a vaccine roll-out, individuals have limited information about the potential side-effects and benefits. Given the public health concern of the COVID pandemic, providing appropriate information fast matters for the success of the campaign. In this paper, time-trends in vaccine hesitancy were examined using a sample of 35,390 respondents from the Eurofound’s Living, Working and COVID-19 (LWC) data collected between 12 February and 28 March 2021 across 28 European countries. The data cover the initial stage of the vaccine roll-out. We exploit the fact that during this period, news about rare cases of blood clots with low blood platelets were potentially linked to the Oxford/AstraZeneca vaccine (or Vaxzeveria). Multivariate regression models were used to analyze i) vaccine hesitancy trends, and whether any trend-change was associated with the link between the AstraZeneca vaccine ii) and blood clots (AstraZeneca controversy), and iii) the suspension among several European countries. Our estimates show that vaccine hesitancy increased over the early stage of the vaccine roll-out (0·002, 95% CI: [0·002 to 0·003]), a positive shift took place in the likelihood of hesitancy following the controversy (0·230, 95% CI: [0·157 to 0·302]), with the trend subsequently turning negative (-0·007, 95% CI: [-0·010 to -0·005]). Countries deciding to suspend the AstraZeneca vaccine experienced an increase in vaccine hesitancy after the suspensions (0·068, 95% CI: [0·04 to 0·095]). Trust in institutions is negatively associated with vaccine hesitancy. The results suggest that SARS-CoV-2 vaccine hesitancy increased steadily since the beginning of the vaccine roll-out and the AstraZeneca controversy and its suspension, made modest (though significant) contributions to increased hesitancy. |
format | Online Article Text |
id | pubmed-9491558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-94915582022-09-22 Information and vaccine hesitancy: Evidence from the early stage of the vaccine roll-out in 28 European countries Agosti, Francesca Toffolutti, Veronica Cavalli, Nicolò Nivakoski, Sanna Mascherini, Massimiliano Aassve, Arnstein PLoS One Research Article The success of mass vaccination programs against SARS-CoV-2 hinges on the public’s acceptance of the vaccines. During a vaccine roll-out, individuals have limited information about the potential side-effects and benefits. Given the public health concern of the COVID pandemic, providing appropriate information fast matters for the success of the campaign. In this paper, time-trends in vaccine hesitancy were examined using a sample of 35,390 respondents from the Eurofound’s Living, Working and COVID-19 (LWC) data collected between 12 February and 28 March 2021 across 28 European countries. The data cover the initial stage of the vaccine roll-out. We exploit the fact that during this period, news about rare cases of blood clots with low blood platelets were potentially linked to the Oxford/AstraZeneca vaccine (or Vaxzeveria). Multivariate regression models were used to analyze i) vaccine hesitancy trends, and whether any trend-change was associated with the link between the AstraZeneca vaccine ii) and blood clots (AstraZeneca controversy), and iii) the suspension among several European countries. Our estimates show that vaccine hesitancy increased over the early stage of the vaccine roll-out (0·002, 95% CI: [0·002 to 0·003]), a positive shift took place in the likelihood of hesitancy following the controversy (0·230, 95% CI: [0·157 to 0·302]), with the trend subsequently turning negative (-0·007, 95% CI: [-0·010 to -0·005]). Countries deciding to suspend the AstraZeneca vaccine experienced an increase in vaccine hesitancy after the suspensions (0·068, 95% CI: [0·04 to 0·095]). Trust in institutions is negatively associated with vaccine hesitancy. The results suggest that SARS-CoV-2 vaccine hesitancy increased steadily since the beginning of the vaccine roll-out and the AstraZeneca controversy and its suspension, made modest (though significant) contributions to increased hesitancy. Public Library of Science 2022-09-21 /pmc/articles/PMC9491558/ /pubmed/36129897 http://dx.doi.org/10.1371/journal.pone.0273555 Text en © 2022 Agosti et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Agosti, Francesca Toffolutti, Veronica Cavalli, Nicolò Nivakoski, Sanna Mascherini, Massimiliano Aassve, Arnstein Information and vaccine hesitancy: Evidence from the early stage of the vaccine roll-out in 28 European countries |
title | Information and vaccine hesitancy: Evidence from the early stage of the vaccine roll-out in 28 European countries |
title_full | Information and vaccine hesitancy: Evidence from the early stage of the vaccine roll-out in 28 European countries |
title_fullStr | Information and vaccine hesitancy: Evidence from the early stage of the vaccine roll-out in 28 European countries |
title_full_unstemmed | Information and vaccine hesitancy: Evidence from the early stage of the vaccine roll-out in 28 European countries |
title_short | Information and vaccine hesitancy: Evidence from the early stage of the vaccine roll-out in 28 European countries |
title_sort | information and vaccine hesitancy: evidence from the early stage of the vaccine roll-out in 28 european countries |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491558/ https://www.ncbi.nlm.nih.gov/pubmed/36129897 http://dx.doi.org/10.1371/journal.pone.0273555 |
work_keys_str_mv | AT agostifrancesca informationandvaccinehesitancyevidencefromtheearlystageofthevaccinerolloutin28europeancountries AT toffoluttiveronica informationandvaccinehesitancyevidencefromtheearlystageofthevaccinerolloutin28europeancountries AT cavallinicolo informationandvaccinehesitancyevidencefromtheearlystageofthevaccinerolloutin28europeancountries AT nivakoskisanna informationandvaccinehesitancyevidencefromtheearlystageofthevaccinerolloutin28europeancountries AT mascherinimassimiliano informationandvaccinehesitancyevidencefromtheearlystageofthevaccinerolloutin28europeancountries AT aassvearnstein informationandvaccinehesitancyevidencefromtheearlystageofthevaccinerolloutin28europeancountries |